Idiopathic pulmonary fibrosis: Disease mechanisms and drug development
P Spagnolo, JA Kropski, MG Jones, JS Lee… - Pharmacology & …, 2021 - Elsevier
… Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease of unknown cause
characterized by relentless scarring of the lung parenchyma leading to reduced quality of life and …
characterized by relentless scarring of the lung parenchyma leading to reduced quality of life and …
Research progress in the molecular mechanisms, therapeutic targets, and drug development of idiopathic pulmonary fibrosis
H Ma, X Wu, Y Li, Y Xia - Frontiers in Pharmacology, 2022 - frontiersin.org
… links in the occurrence and development of pulmonary fibrosis. The M2-mediated … of
pulmonary fibrosis. M2 macrophages provide an important microenvironment for pulmonary fibrosis …
pulmonary fibrosis. M2 macrophages provide an important microenvironment for pulmonary fibrosis …
Current and novel drug therapies for idiopathic pulmonary fibrosis
HI Adamali, TM Maher - Drug Design, Development and Therapy, 2012 - Taylor & Francis
… , physicians, clinical and basic scientists, and the pharmaceutical industry to find definitive
treatments for idiopathic pulmonary fibrosis (IPF). As understanding of disease behavior and …
treatments for idiopathic pulmonary fibrosis (IPF). As understanding of disease behavior and …
Drug discovery and development in idiopathic pulmonary fibrosis: challenges and opportunities
S Cruwys, P Hein, B Humphries, D Black - Drug Discovery Today, 2020 - Elsevier
… In summary, drug discovery and development in IPF appear to be crowded areas and with
several challenges. The preclinical studies need to be better designed taking into account the …
several challenges. The preclinical studies need to be better designed taking into account the …
A Long and Winding Road: Drug Development in Idiopathic Pulmonary Fibrosis
P Spagnolo, TM Maher - … of Respiratory and Critical Care Medicine, 2024 - atsjournals.org
… These failures highlight a number of issues, including our limited understanding of the
systems biology of pulmonary fibrosis, the inefficiency of current IPF trial design and endpoints, …
systems biology of pulmonary fibrosis, the inefficiency of current IPF trial design and endpoints, …
Shedding light on developmental drugs for idiopathic pulmonary fibrosis
P Spagnolo, F Bonella, CJ Ryerson… - … Investigational Drugs, 2020 - Taylor & Francis
… The approval of pirfenidone and nintedanib has fueled IPF drug discovery and development.
New drugs are likely to reach the clinic in the near future. However, numerous challenges …
New drugs are likely to reach the clinic in the near future. However, numerous challenges …
Idiopathic pulmonary fibrosis: recent trials and current drug therapy
MG Jones, S Fletcher, L Richeldi - Respiration, 2013 - karger.com
… provided essential insights into trial design, including patient selection and … drug therapy,
practical issues when applying RCT findings to an individual patient with IPF and trial design …
practical issues when applying RCT findings to an individual patient with IPF and trial design …
Idiopathic pulmonary fibrosis: Current and future treatment
DS Glass, D Grossfeld, HA Renna… - The clinical …, 2022 - Wiley Online Library
… lung disease characterized by dry cough, fatigue, and … use and those that appear
promising for future development. … , but hepatotoxicity may occur in rare cases and the drug is …
promising for future development. … , but hepatotoxicity may occur in rare cases and the drug is …
Idiopathic pulmonary fibrosis: recent advances on pharmacological therapy
P Spagnolo, TM Maher, L Richeldi - Pharmacology & therapeutics, 2015 - Elsevier
… Yet, clinical trials can be pursued, almost exclusively, by industry because of the enormous
financial investment and logistic network required for successful drug development. The last …
financial investment and logistic network required for successful drug development. The last …
Newer developments in idiopathic pulmonary fibrosis in the era of anti-fibrotic medications
GB Nair, A Matela, D Kurbanov… - … of respiratory medicine, 2016 - Taylor & Francis
… Drug development programs have focused on mitigating several of these pathways and are
… Until recently, treatment options for idiopathic pulmonary fibrosis were limited. Over the last …
… Until recently, treatment options for idiopathic pulmonary fibrosis were limited. Over the last …
相关搜索
- idiopathic pulmonary fibrosis drug targets
- idiopathic pulmonary fibrosis drug therapies
- idiopathic pulmonary fibrosis drug treatments
- idiopathic pulmonary fibrosis molecular mechanisms
- idiopathic pulmonary fibrosis clinical trials
- idiopathic pulmonary fibrosis newer developments
- management of idiopathic pulmonary fibrosis
- pathogenesis of idiopathic pulmonary fibrosis
- burden of idiopathic pulmonary fibrosis
- idiopathic pulmonary fibrosis patients
- idiopathic pulmonary fibrosis unsolved issues
- idiopathic pulmonary fibrosis disease mechanisms
- idiopathic pulmonary fibrosis cytokine pathways
- idiopathic pulmonary fibrosis investigational approaches
- idiopathic pulmonary fibrosis more work
- idiopathic pulmonary fibrosis pooled data analyses